Prosecution Insights
Last updated: September 23, 2026

Aspect Biosystems Ltd.

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (67%)
1
Medium (33%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (33%)
Multi-statute (no §101)2 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SWANSON, ANDREW L 1 66.5% +11.6%
HAGOPIAN, CASEY SHEA 1 54.4% +33.3%
DHAR, MATASHA 1 43.3% +45.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18686755 MICROFLUIDIC-BASED FIBER FORMATION METHODS AND SYSTEMS SWANSON, ANDREW L —
18563872 SELECTIVELY PERMEABLE ANNULUS FIBERS AND METHODS OF USING SAME HAGOPIAN, CASEY SHEA —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18022538 METHOD FOR SCREENING IN VITRO POPULATION OF STEM CELL DERIVED BETA LIKE CELLS AND NOVEL MARKERS THEREOF DHAR, MATASHA 31d overdue
18686755 MICROFLUIDIC-BASED FIBER FORMATION METHODS AND SYSTEMS SWANSON, ANDREW L —
18563872 SELECTIVELY PERMEABLE ANNULUS FIBERS AND METHODS OF USING SAME HAGOPIAN, CASEY SHEA —

Top Art Units

Art UnitApps
1745 1
1617 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18686755 MICROFLUIDIC-BASED FIBER FORMATION METHODS AND SYSTEMS SWANSON, ANDREW L 1745 §103§112 Non-Final OA — Pending Feb 26, 2024
18563872 SELECTIVELY PERMEABLE ANNULUS FIBERS AND METHODS OF USING SAME HAGOPIAN, CASEY SHEA 1617 §103§112 Non-Final OA — Pending Nov 22, 2023
18022538 METHOD FOR SCREENING IN VITRO POPULATION OF STEM CELL DERIVED BETA LIKE CELLS AND NOVEL MARKERS THEREOF DHAR, MATASHA 1632 §102 Non-Final OA 31d overdue Pending Feb 22, 2023

Managing Aspect Biosystems Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month